AOD-9604

AOD-9604 is a synthetic 16-amino-acid peptide derived from the fat-mobilizing region of human growth hormone (hGH). It was designed to preserve fat-burning effects while avoiding the side effects of full hGH, such as raised insulin-like growth factor 1 (IGF-1) and insulin resistance. Safety and tolerability of the hexadecapeptide AOD9604 in humans+1

Despite early promise in animal studies, human research found it does not reliably produce weight loss. In six randomized trials with over 900 people, the peptide did not outperform placebo for weight loss. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance However, it was well tolerated short-term, with no signs of GH-like hormonal disruption. Safety and tolerability of the hexadecapeptide AOD9604 in humans

How it works differently from growth hormone

AOD-9604 acts on fat cells to increase lipolysis (fat release) and fat oxidation, likely through beta-adrenergic pathways, not through the GH receptor. This mechanism is distinct from GH, which explains why it does not stimulate IGF-1 or cell growth. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice andβ 3-AR knock-out mice+1 The fragment corresponds to amino acids 177-191 of hGH, with an extra tyrosine for stability. Detection and <i>in vitro</i> metabolism of AOD9604

AOD-9604 is a fragment of human growth hormone (amino acids 177-191) with an extra tyrosine for stability. It was designed to mimic the fat-mobilizing part of GH without binding to the GH receptor. This means it does not stimulate IGF-1 production or cell growth, unlike full GH. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice andβ 3-AR knock-out mice+1

In fat cells, it appears to increase lipolysis (fat breakdown) and the use of fat for energy, partly through beta-adrenergic signaling. In mice, its weight-reducing effects depended on beta-3 adrenergic receptors, indicating that this pathway is important. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice andβ 3-AR knock-out mice

However, in human obesity trials, the peptide did not lead to significant weight loss, suggesting that the pathway may not be strong enough or that the doses used were insufficient. Safety and tolerability of the hexadecapeptide AOD9604 in humans+1 The compound's effect on cartilage in animal studies points to local regenerative actions, but the receptor remains unknown. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model

The documented effects of AOD-9604 are mixed. In animal studies, it increased fat oxidation and reduced body-weight gain, with higher levels of glycerol in the blood, a sign of enhanced lipolysis. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice andβ 3-AR knock-out mice+1

However, in six randomized, placebo-controlled human trials with over 900 participants, the peptide did not show a statistically significant dose-dependent effect on weight loss. Safety and tolerability of the hexadecapeptide AOD9604 in humans+1 Short-term safety was favorable, with no changes in IGF-1 or insulin sensitivity. Safety and tolerability of the hexadecapeptide AOD9604 in humans

Preclinical joint effects

In a rabbit model of osteoarthritis, weekly knee injections of AOD-9604 improved cartilage health, especially when combined with hyaluronic acid. But this has not been tested in humans. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model

Overall, the research suggests that while AOD-9604 can influence fat metabolism, it is not an effective weight-loss treatment. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

Research protocols for AOD-9604 have used oral routes in human obesity studies, though community practice has shifted to injectable forms. Safety and tolerability of the hexadecapeptide AOD9604 in humans The typical protocol involves daily dosing for 8-12 weeks, but because human trials failed to establish efficacy, there is no validated dose. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

Animal studies used oral doses of 500 mcg/kg/day in rats, which cannot be directly applied to humans. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment In the absence of proven dosing guidelines, any use of AOD-9604 remains experimental and should be approached with caution.

Common community approaches

Despite the negative trials, many self-experimenters use subcutaneous injections of 250-500 mcg daily, often fasted in the morning. These protocols are not supported by clinical efficacy data. The timeline on the screen shows a representative research schedule based on this practice.

AOD-9604 is often sold as a lyophilized powder that must be mixed with bacteriostatic water before injection. The vial sizes and concentrations vary because it is not a pharmacy-grade pharmaceutical. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market+1

Peptide products seized from the market have shown impurities and mislabeling, so sterility and accurate dosing cannot be guaranteed. Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604+1 For research, storage at 2-8°C after mixing is typical, and use within 28-45 days is recommended to minimize degradation. This guidance comes from community protocols, not from a formal stability study. Detection and <i>in vitro</i> metabolism of AOD9604+1

Because the exact half-life in solution is not well characterized, it's best to prepare small batches and avoid repeated freeze-thaw cycles. The interactive calculator below can help with concentration math.

Human drug interaction studies are not available for AOD-9604. Based on its mechanism, the main theoretical concern is combining it with stimulants (caffeine, phentermine, etc.) because AOD-9604 may enhance beta-adrenergic signaling, potentially leading to increased heart rate, palpitations, or blood pressure. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice andβ 3-AR knock-out mice+1

It does not raise IGF-1, so it is unlikely to interfere with growth hormone therapies. Safety and tolerability of the hexadecapeptide AOD9604 in humans Using it alongside GLP-1 drugs for weight loss would likely add little benefit since AOD-9604 itself has not shown efficacy. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

Condition-related risks

People with autonomic disorders (such as POTS) or uncontrolled hypertension should use extreme caution, as beta-adrenergic stimulation could worsen symptoms. Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management There is no evidence of cytochrome P450 interactions, but the lack of data means caution is warranted with any drug that affects heart rate or metabolism.

Cycling AOD-9604 is common practice, with typical cycles of 8-12 weeks followed by an off period of 2-4 weeks. This pattern is not based on evidence of tolerance but rather on the lack of long-term safety data and the failure to demonstrate ongoing benefit beyond short-term experiments. Safety and tolerability of the hexadecapeptide AOD9604 in humans+1

Since the peptide does not stimulate IGF-1 or suppress hormones, there is no known need for post-cycle recovery. However, long-term adrenergic stimulation is a theoretical risk, making breaks prudent. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice andβ 3-AR knock-out mice+1

When to take a break

If no objective change in body composition occurs by week 6-8, extending the cycle is unlikely to help, and a break should be considered. Any new onset of palpitations, tremor, or orthostatic lightheadedness is a clear signal to stop. Safety and tolerability of the hexadecapeptide AOD9604 in humans+1

AOD-9604 is often stacked with other compounds in research for fat loss, such as growth hormone secretagogues (CJC-1295, ipamorelin) or GLP-1 receptor agonists. The rationale is to combine different metabolic pathways, but there is no trial evidence that stacking improves outcomes.

Because AOD-9604 does not work through the GH receptor, it may not duplicate effects of GH peptides, but it also may not add measurable fat loss. Safety and tolerability of the hexadecapeptide AOD9604 in humans+1 The greatest risk comes from combining it with stimulants, which could amplify cardiovascular side effects. Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management

Preclinical synergy

In a rabbit osteoarthritis model, AOD-9604 combined with hyaluronic acid improved cartilage repair more than either alone, suggesting a potential local synergy. This has no human confirmation. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model

AOD-9604 is not approved by the FDA or any other regulatory agency for medical use. Its development for obesity was discontinued after Phase II trials failed to show sufficient efficacy. Central and peripheral molecular targets for antiobesity pharmacotherapy+1 It is classified as an unapproved peptide and is not legally available for prescription.

In sports, AOD-9604 is prohibited by WADA and is detectable in urine drug tests. AOD-9604 does not influence the WADA hGH isoform immunoassay+1 Athletes should not use it. The peptide circulates through unregulated channels, with seized samples confirming the risk of mislabeled or impure products. Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604+1

Overall, short-term use of AOD-9604 in human trials was well tolerated, with no significant changes in IGF-1, insulin sensitivity, or blood pressure. Safety and tolerability of the hexadecapeptide AOD9604 in humans However, there are no long-term safety data.

The peptide's mechanism raises theoretical concerns about prolonged stimulation of the sympathetic nervous system, which could lead to palpitations, anxiety, or orthostatic intolerance in sensitive individuals. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice andβ 3-AR knock-out mice+1 The biggest practical risk is using unregulated, possibly mislabeled products from the internet, as seized samples have contained impurities. Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604+1

What to watch

Red flags include resting tachycardia, new-onset tremor, or unexplained glucose shifts. If these occur, the compound should be discontinued immediately. People with pre-existing heart conditions or autonomic dysfunction should avoid it. Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management